Scientists have developed the world’s first drug shown to work against Alzheimer’s disease.
Lecanemab reduced decline in memory and thinking skills by 27% over 18 months in a trial of 1,800 people with early-stage Alzheimer’s.
It is the only drug to treat the underlying disease, not just temporarily manage symptoms. It may be available to British patients with early-stage Alzheimer’s in two to three years.
